• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Orgenesis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    9/16/25 5:29:47 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORGS alert in real time by email
    false 0001460602 0001460602 2025-09-16 2025-09-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 16, 2025

     

    ORGENESIS INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-38416   98-0583166
    (State or other jurisdiction   (Commission File   (IRS Employer
    of incorporation   Number)   Identification No.)

     

    20271 Goldenrod Lane, Germantown, MD 20876

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (480) 659-6404

     

    Not Applicable

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   ORGS   N/A

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On September 10, 2025, Theracell Laboratories IKE (“Theracell”), a subsidiary of Octomera LLC, which is a subsidiary of Orgenesis Inc. (the “Company”), entered into a Convertible Loan Agreement (the “Agreement”) with Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P (the “Lender”).

    Pursuant to the Agreement, the Lender agreed to provide Theracell with an initial loan in the principal amount of $1,000,000 (the “Loan”). The Loan will bear simple interest at a rate of 10% per annum and has a maturity of 36 months. For the first 30 days following the effective date, the Borrower may prepay the Loan without the consent of the Lender. Thereafter, repayment requires the Lender’s prior approval.

    Beginning after 30 days and continuing until maturity, the Lender has the option, at its sole discretion, to convert the outstanding amount into equity of either the Company or Theracell, such that the Lender would hold up to 80% of the outstanding share capital of the applicable entity. The conversion of the Loan into shares of the Company is subject to shareholder approval of the issuance of the required shares.

    In addition, the Agreement provides that the Lender will be issued a warrant to purchase 15% of the fully diluted share capital of either the Company or Theracell, at the Lender’s discretion, for an aggregate exercise price of $250,000 and exercisable for three years from issuance. The issuance of shares upon exercise of the warrant is likewise subject to shareholder approval of the issuance of such shares. Additional warrants would be issued in connection with each cumulative drawdown of an additional $1,000,000 under the credit facility referenced below.

    The Agreement further provides Theracell with access to a credit facility of up to $10,000,000, available in tranches with the Lender’s prior written approval in its sole discretion. Drawdowns under the facility are subject to the same terms as the Loan, other than the conversion feature. Theracell has drawn $7,083,857 on the facility. The previously outstanding debt facilities from Newtech Investment Holdings, LLC and Ariel Malik totaling $6,083,857 have been repaid.

    The Agreement also provides that, following the lapse of 30 days from the Effective Date and subject to the receipt of all necessary corporate and legal approvals, the Lender may appoint three members to the Company’s Board of Directors, which appointments will be subject to the disclosure and filing requirements of the Securities Exchange Act of 1934 and the rules of the Securities and Exchange Commission.

    The Agreement includes customary covenants and security provisions, including security interests over certain assets.

    The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Convertible Loan Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K. Appendices and certain schedules to the Agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish a copy of any omitted appendix or schedule to the SEC upon request.

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information required by this Item 2.03 is included under Item 1.01 of this Current Report on Form 8-K.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
         
    10-1Convertible Loan Agreement, dated September 10, 2025, by and among Theracell Laboratories IKE, Orgenesis Inc., and Alpha Prosperity Fund SPC (certain appendices, exhibits and schedules omitted).
       
     104  Cover Page Interactive Data File (embedded with the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ORGENESIS INC.
       
    Date: September 16, 2025 By: /s/ Vered Caplan
        Vered Caplan
        Chief Executive Officer
         

     

     

     

     

    Get the next $ORGS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORGS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ORGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Safier Jacob bought $16,883 worth of shares (30,000 units at $0.56) and sold $16,259 worth of shares (30,000 units at $0.54) (SEC Form 4)

    4 - Orgenesis Inc. (0001460602) (Issuer)

    12/4/24 6:48:38 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Safier Jacob bought $3,332 worth of shares (10,100 units at $0.33) (SEC Form 4)

    4 - Orgenesis Inc. (0001460602) (Issuer)

    2/14/24 9:32:21 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Safier Jacob bought $213,280 worth of shares (365,140 units at $0.58) (SEC Form 4)

    4 - Orgenesis Inc. (0001460602) (Issuer)

    2/14/24 9:31:52 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGS
    SEC Filings

    View All

    Orgenesis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Orgenesis Inc. (0001460602) (Filer)

    9/16/25 5:29:47 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Orgenesis Inc. (0001460602) (Filer)

    8/25/25 4:30:43 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Orgenesis Inc. (0001460602) (Filer)

    8/19/25 4:30:51 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Malik Ariel claimed ownership of 1,200,000 shares (SEC Form 3)

    3 - Orgenesis Inc. (0001460602) (Issuer)

    3/18/25 4:06:38 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Vider Itzhak

    4 - Orgenesis Inc. (0001460602) (Issuer)

    12/16/24 2:42:24 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Adler Yaron

    4 - Orgenesis Inc. (0001460602) (Issuer)

    12/16/24 2:42:29 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Orgenesis Provides Third Quarter 2024 Business Update

    GERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCQX: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the third quarter ended September 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "Orgenesis is making significant progress in redefining accessibility to cell and gene therapies through our decentralized approach. This model is designed to expedite capacity setup, enhance production efficiency, and reduce treatment costs. We are dedicated to expanding our clinical initiatives and deepening gl

    11/13/24 8:00:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Commences Trading on OTCQX® Best Market

    Reports Plans to Reapply for Nasdaq Listing Announces Progress Advancing Decentralized Cell Processing Platform GERMANTOWN, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that its common stock will begin trading on the OTCQX® Best Market under the ticker symbol "ORGS" following its delisting from the Nasdaq Stock Market. The delisting resulted from the Company's failure to meet the required stockholders' equity threshold. Orgenesis plans to attempt to resolve the deficienc

    10/21/24 8:00:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Announces Reverse Stock Split

    GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company") today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company's existing trading symbol "ORGS". The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq C

    9/23/24 7:00:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGS
    Financials

    Live finance-specific insights

    View All

    Orgenesis Provides Second Quarter 2024 Business Update

    GERMANTOWN, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the second quarter ended June 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "After more than a decade of parallel efforts—on one hand, establishing robust capabilities in cell therapy production by initially serving the industry in a centralized manner and later integrating these capabilities into a decentralized platform, and on the other, forming partnerships through joint ve

    8/8/24 4:05:00 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

    GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has entered into a definitive agreement with MM OS Holdings L.P., an affiliate of Metalmark Capital Partners ("Metalmark"), for the acquisition of its approximate 25% stake in Octomera LLC ("Octomera"), the cell processing services subsidiary of the Company, thereby allowing the Company to have 100% ownership of this core strategic business unit. In exchange, Metalmark shall receive a royalty of 5% of the net revenue of Octomera's cell processing services, for the three calendar years 2025-2027,

    1/31/24 9:15:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Provides Business Update for Second Quarter of 2023

    Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the second quarter ended June 30, 2023. Vered Caplan, CEO of Orgenesis, said, "We are pleased to report revenue of approximately $7.0 million for the second quarter of 2023, which reflects the ongoing rollout of our POCare platform. We recently rebranded the POC Servic

    8/11/23 7:00:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGS
    Leadership Updates

    Live Leadership Updates

    View All

    Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

    GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the infrastructure of the advanced therapeutic POCare services and facilities supply business, Octomera. The appointment of Gerhard Bauer as the Vice President of Global Product Implementation at Octomera has been made to enhance the existing process development, regulatory, engineering, equipment, and data/technical service offering and POCare Center hubs. He is also an active contributor to the evolution of the flexible facilities format, Octomera Mobile Process Labs & Units (OMPULs) and network, which allow the

    9/6/23 7:00:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

    GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced the appointment of Elliot Maltz as Chief Financial Officer, effective September 1, 2023. Mr. Maltz succeeds Mr. Neil Reithinger, who is resigning following years of dedicated service and will remain with the Company until he completes his transition of duties, through September 1, 2023. Mr. Maltz brings 16 years of accounting and corporate finance experience working with public and private companies, specializing in the biotechnology, medical devic

    7/13/23 8:30:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Proactive news headlines including Altamira Gold, AIM ImmunoTech, QC Copper and Gold and Cloud Nine Education

    New York, March 08, 2021 (GLOBE NEWSWIRE) -- - Altamira Gold Corp (CVE:ALTA) (OTCPINK:EQTRF) (FRA:T6UP) reveals four high-grade gold and silver vein structures at its Apiacas project in Brazil click here - Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) teams with Dong-a University Hospital in South Korea and Cure Therapeutics to utilize its Mobile Processing Units and Labs, or OMPULs click here - QC Copper and Gold Inc (CVE:QCCU) (OTCMKTS:QCCUF) updates on Opemiska drill progress and names new independent director click here - AIM ImmunoTech Inc (NYSEAMERICAN:AIM) doses first healthy subject in intranasal Ampligen coronavirus study click here - Alpine 4 Technologies Inc (OTCQB:ALPP) say

    3/8/21 2:36:14 PM ET
    $TCON
    $ORGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ORGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:51:18 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:50:26 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Orgenesis Inc. (Amendment)

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    2/14/24 8:16:04 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care